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Summary 
T  lymphocytes play a pivotal role in the immune response during viral infections. In a murine 
model of experimental respiratory syncytial virus (tLSV)  infection, mice sensitized to either of 
the two major glycoproteins of RSV develop distinct patterns of cytokine secretion and lung 
inflammation upon subsequent ILSV infection. Mice sensitized to I<SV-G (attachment) glyco- 
protein exhibit a strong interleukin  (IL)-4 and IL-5 response and develop pulmonary eosino- 
phiha,  whereas  mice sensitized  to  tLSV-F  (fusion)  glycoprotein develop  a predominantly T 
helper cell (Th)1 response and pulmonary inflammation characterized by mononuclear cell in- 
filtration. In this study, we examined the potential role of virus-specific CD8 + T  cytolytic T  cells 
on the differentiation and activation of functionally distinct CD4 + T  cells specific to these viral 
glycoproteins. Mice primed with recombinant vaccinia virus expressing RSV-F glycoprotein 
mounted a strong tkSV-specific, MHC  class I-restricted cytolytic response, whereas priming 
with recombinant vaccinia virus expressing I<SV-G glycoprotein failed to elicit any detectable 
cytolytic response. Priming for a tLSV-specific CD8 + T  ceil response, either with a recombi- 
nant vaccinia virus expressing tLSV-G glycoprotein in which  a strong CD8 ÷ T  cell epitope 
from P,  SV-M2 (matrix) protein has been inserted or with a combination of vaccinia virus ex- 
pressing the  matrix protein  and the tLSV-G glycoprotein, suppressed the  eosinophil recruit- 
ment into  the lungs  of these mice upon subsequent  challenge with tLSV.  This reduction  in 
pulmonary eosinophilia correlated with the suppression of Th2 type cytokine production. The 
importance ofCD8 + T  cells in this process was further supported by the results in CD8 + T  cell 
deficient,  [32 microglobulin KO mice. In these mice, priming to tLSV-F glycoprotein (which 
in  normal  mice  primed for a  strong  cytolytic  response  and  a  pulmonary infiltrate  consisting 
primarily of mononuclear cells on tkSV challenge) resulted in the development of marked pul- 
monary eosinophilia  that was  not  seen  in  mice with  an intact  CD8 +  T  cell  compartment. 
These results indicate that CD8 + T  cells may play an important role in the regulation of the 
differentiation and activation of Th2  CD4 + T  cells  as well as the recruitment of eosinophils 
into the lungs during tLSV infection. 
M 
ultiple  arms of the immune system are activated in 
.response to infection by foreign organisms. The out- 
comes of the infection, such as the clearance of the organ- 
isms and the  generation of tissue injury,  depend  on these 
immune effector mechanisms that are mobilized against the 
pathogen. The role of T  cells  in the immune response to 
viral infections has been clearly established (1, 2). Mature 
T  cells that express el/J3 T  cell receptors can be divided into 
ceils expressing either CD4 or CD8 surface antigen. CD8 + 
T  ceils recognize processed antigen in the context of MHC 
class I molecules, whereas CD4 + T  cells recognize peptides 
in the context of MHC class II molecules (3, 4).  The con- 
ventional view ofCD8 + T  cells has been primarily the kill- 
ing of virally infected cells by direct cytolysis or by cyto- 
kines secreted by these T  cells such as IFN-~/and TNF (1, 
2). Functional subsets of CD4 + T  cells have been described 
based on the cytokines produced by these cells, Thl CD4 + 
T  cells that secrete IL-2 and IFN-y and Th2 T  cells that se- 
crete IL-4 and IL-5 (5,  6).  The physiological relevance of 
these  subsets  of T  cells  with  diverse functions  have been 
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ratory syncytial virus (RSV) ~. 
In the murine  model of RSV infection,  the  roles of T 
cells and their products in the eradication of the virus as well 
as  the  pathogenesis of lung  inflammation have  been  well 
documented  (7-12).  Recent studies have shown that mice 
sensitized to  either of the two  major glycoproteins of this 
virus developed distinct lung pathology when subsequently 
infected with RSV (12-15).  Mice sensitized to the attach- 
ment glycoprotein (G)  of RSV developed pulmonary eo- 
sinophilia that correlated with a strong induction of Th2 type 
response, whereas mice primed to the fusion (F) glycopro- 
tein mounted a weak Th2 response and developed lung in- 
fla  arion characterized by mononuclear cell infiltration. 
The underlying mechanisms that lead to these apparent dis- 
tinct patterns of cytokine production and lung injury still 
remain unclear. 
The process by which CD4 + T  cells mature and differ- 
entiate  has  been  the  subject  of intense  investigation  (16). 
CD4 +  T  cells can be induced to differentiate into effector 
cells of either the  Thl  or Th2  subsets,  depending on  the 
milieu in which these cells are activated. Cytokines such as 
IL-4 and  IL-12 have been shown  to play a  crucial part in 
the regulation of CD4 + T  cell differentiation (17-19).  The 
presence  of certain immune  eflE~ctor functions  during the 
differentiation and expansion of CD4 + T  cells may poten- 
tially be a key factor in determining the functional pheno- 
types acquired by these cells. In the murine model of ex- 
perimental RSV infection, one important difference in the 
immune  response  to  F  and  G  glycoprotein of RSV is the 
lack of MHC  class I-restricted cytolytic response to the G 
glycoprotein (13, 20). In the following studies, we began to 
investigate the impact  of CD8 +  T  cells and MHC  class 
I-restricted  CTL  responses  on  cytokine  secretion  and  the 
subsequent  development of pulmonary eosinophilia dur- 
ing experimental murine  RSV infection.  We  have  found 
that the induction ofCD8 + T  cell response to RSV proteins 
resulted in dramatically decreased levels of Th2 type cytokines 
and eosinophil recruitment into the lungs of RSV-infected 
mice previously sensitized to the RSV-G glycoprotein. The 
possible mechanisms underlying these observations and their 
potential significance are discussed. 
backcrossed into the BALB/c background, and were screened for 
the absence of MHC class I expression. They were homozygous 
for the H-2  d haplotype at the MHC class II locus as judged by the 
absence of the expression of I-A  b and the presence of I-A  d mole- 
cules detected by flow cytometric analysis of spleen cells. These 
mice were maintained in pathogen-free conditions. 
Virus and Infection of Mice.  Recombinant  vaccinia  virus  ex- 
pressing RSV fusion glycoprotein (VF) and RSV attachment gly- 
coprotein (VG)  were  obtained from J.L.  Beeler (Federal Drug 
Administration, National  Institutes of Health).  The  generation 
and characterization of these virus have been previously described 
(22,  23). Recombinant vaccinia viruses expressing only [3-galac- 
tosidase (VSC11) insertion vector was used as a control. RSV (A2 
strain)  was a gift from P.L. Collins (National Institute of Allergy 
and Infectious Diseases,  National Institutes of Health). RSV was 
grown on HEp-2 cells and plaque purified. The virus stock was 
grown in HEp-2 cells and titered for infectivity. Mice were in- 
fected with 3  ×  106 PFU of recombinant vaccinia virus by scari- 
fication at  the  base  of tail.  In  experiments  where  mice  were 
primed with two recombinant vaccinia viruses, equal numbers 
(3 ×  106 PFU) of each recombinant virus were used to prime the 
animals. In some experiments, the mice were given 106 PFU of 
RSV in 50 txl inoculum intranasally 3 wk after priming and killed 
5 d later. Cells were isolated from the lungs for in vitro culture. 
Lung tissue was prepared for histopathology. 
Construction of Recombinant Vaccinia Virus.  PGEM3 plasmid vec- 
tor containing the cDNA for RSV-G glycoprotein was a gift from 
P.L. Collins (National Institute of Allergy and Infectious Diseases, 
National  Institutes  of  Health).  Synthetic  double-stranded  oli- 
gonucleotides encoding the immunodominant epitope from the 
RSV-M2  protein  (amino  acid residues 82-90;  24)  were  made 
(Biomolecular Research Facility, University of Virginia, Charlottes- 
ville, VA). The oligonucleotides were inserted into the NdeI site 
ofcDNA encoding the RSV-G protein (Fig. 1). The correct se- 
quence and the orientation of the inserted nucleotide were con- 
firmed by sequencing. The portion of the cDNA encoding the G 
protein with inserted 22K epitope (G22K) was then cloned into a 
modified version  of PSCll  plaslnid vector.  The  recombinant 
vaccinia virus expressing this protein (VG22K) was then gener- 
ated by a method previously described (22). 
Histopathology.  Lungs  of mice  were  harvested and  fixed in 
10% formalin in PBS. The specimens were processed, embedded, 
and sectioned by American Histolabs Inc.  (Gaithersburg, MD). 
Sections of the lungs were prepared and stained for eosinophils by 
the Leinert-Giemsa technique. To  compare the degree of tissue 
eosinophilia in the sections, we enumerated cells with characteris- 
Materials and Methods 
Mice.  Female BALB/c  (H-2  a)  mice age 8-12  wk old were 
purchased from Taconic Farms Inc.  (Germantown,  NY).  Mice 
with disrupted [32  microglobulin ([32m) genes were bred from 
stock initially provided by T.  Hansen  (Washington University, 
St.  Louis,  MO).  The  generation  and  characterization of these 
mice  have  been  described previously  (21).  These  mice  were 
1Abbreviations used in this paper: [32m, [32 microglobulin; G22K, portion of 
cDNA encoding the G protein with inserted 22K epitope; RSV, respira- 
tory syncytial virus; V22K, recombinant vaccinia virus expressing RSV 
matric (M2 or 22K) protein; VF, recombinant vaccinia virus expressing 
RSV  fusion glycoprotein; VG,  recombinant  vaccinia virus expressing 
RSV attachment glycoprotein; VG22K, recombinant vaccinia virus ex- 
pressing chimeric G/22K glycoprotein. 
RSV-G cDNA 
NdeI 
|  • 
V  P  C  S  I  IS  Y  I  G  S  I  N  N  I|  C 
TTGTACCCTG  CAGCATAAGT  TATATAGGAT  CAATAAACAA  TATATGC 
AACATGGGAC  GTCGTATTCA  ATATATCCTA  GTrAXTTGTT  ATATACG 
Figure 1.  Construction of cDNA encoding RSV-G glycoprotein con- 
taining a CTL epitope of  RSV-M2(22K) protein. The indicated oligonu- 
cleotide heteroduplex (bold) was introduced into the NdeI site at base 535 
of the RSV-G cDNA.  The synthetic oligonucleotide encodes the nine 
residues SYIGSINNI from amino acids 82-90 of the RSV-M2(22K) ma- 
trix protein. 
422  Downregulation of Th2 Response by Virus-specific CD8 + T Cells tic eosinophil staining in and around blood vessel walls. The length 
of individual vessels was estimated using a micrometer attached to 
the eyepiece of microscope. The results were expressed as num- 
ber of eosinophils present per millimeter of blood vessel. 
Lymphocyte Culture.  Cells were isolated from lung tissue  by 
collagenase digestion as previously described (25).  In brief, lungs 
were  minced  in  Iscove's media  (GIBCO  BRL,  Gaithersburg, 
MD) containing 10% fetal calf serum and incubated with collage- 
nase D  (Boehringer Mannheim, Indianapolis, IN) at final concen- 
tration of 0.7  mg/ml.  The  digestion was  done  at 37°C  for 90 
rain. The digested lung tissue was tapped through a wire screen. 
Particulate matter was removed by a quick centrifugation at 1,000 
rpm. The cell suspension was layered over a Ficoll-Hypaque density 
gradient, (Lymphocyte-M; Cedarlane Labs. Ltd., Ontario, Canada) 
and centrifuged at 400 g for 15 min. The mononuclear cells at the 
interface were  isolated and used in in vitro culture.  Single cell 
suspensions were isolated from a  spleen by grinding the spleen 
through a wire screen followed by a quick centrifugation.  Cells were 
cultured at indicated cell numbers  with  irradiated naive  spleen 
cells infected with RSV at a multiplicity of infection of 0.1. The 
ratio ofresponders to stimulators was, in general, 5:1. 
Detection of Cytokines in Culture Supernatants.  Supematants  from 
in vitro culture of cells isolated from spleens or lungs were col- 
lected at 48 h after stimulation and kept at -70°C until analyzed. 
The concentrations of IL-2, IL-4, IL-5, and IFN-'y in these su- 
pernatants were measured using commercial ELISA reagents un- 
der conditions recommended by the manufacturer (PharMingen, 
San Diego, CA). 
Assays  for Cell-mediated Cytotoxicity.  The  SlCr-release  cyto- 
toxicity assay was performed as previously described (2). Mastocy- 
toma cells (I7815) expressing compatible MHC class I (I-1-2  a) were 
used for these assays as targets. Target cells either uninfected or 
infected with indicated virus were incubated with SlCr overnight 
at room temperature, and then washed twice and plated at 5  × 
103  cells/well in a 96-well, flat-bottom, tissue  culture plate. Ef- 
fector cells were  added at  variable cell number  to  appropriate 
wells in quadruplicate. The plates were incubated at 37°C in 10% 
CO2 for 6 h. 100  p~l of supernatant was harvested from each well 
and counted on a gamma counter (Isomedic; ICN Biomedicals, 
Inc., Costa Mesa, CA). The percent lysis was calculated as previ- 
ously described (2). 
Results 
Cytolytic  Activity  of RSV-F-  and  RSV-G-specific  Spleen 
Cells.  In previous reports, we and others have shown that 
in BALB/c mice, the cytokine response of CD4 +  T  lym- 
phocyte primed to the two major glycoproteins of RSV are 
distinct (12-14). Mice primed with a recombinant vaccinia 
virus expressing the RSV-G glycoprotein mounted a strong 
Th2-like cytokine response and developed lung inflamma- 
tion  characterized by  intense  eosinophil infiltration upon 
challenge with  infectious RSV.  On  the  other hand,  mice 
sensitized to the RSV-F glycoprotein mounted a Thl-like 
cytokine response  and  developed lung inflammation con- 
sisting of mononuclear cell infiltrates with few eosinophils 
after RSV challenge (12,  14). 
To  study the  mechanisms  underlying this  difference in 
responsiveness of immune  CD4 + T  cells, we evaluated as- 
pects  of the  immune  response  to  these  two  proteins  that 
could potentially influence the cytokine response of G- or 
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Figure 2.  RSV-specific (A) and vaccinia vires-specific (B) cytolytic re- 
sponses in mice primed with recombinant vaccinia virus expressing  RSV-F 
(VF) or RSV-G (VG) glycoprotein. Splenocytes from mice previously 
primed with VF or VG were stimulated in vitro with RSV-infected naive 
spleen cells (A) or spleen cells infected with recombinant vaccinia virus 
not expressing RSV antigen (B). RSV-specific and vaccinia-specific  cy- 
tolytic activity of these bulk cultures against target cells uninfected or in- 
fected with indicated recombinant vaccinia virus were analyzed in a stan- 
dard SlCr assay. 
F-specific CD4 + T  cells and the type of pulmonary pathol- 
ogy observed after RSV infection. An important difference 
in the immune  response to these two  glycoproteins lies in 
the ability of these proteins to elicit an MHC  class I-restricted 
cytolytic response. Previous studies in the mouse (13, 20) indi- 
cated that RSV-G does not induce a MHC  class I-restricted 
cytolytic response either after RSV infection or after prim- 
ing with VG, whereas a vigorous CTL response to RSV-F 
is observed after RSV  infection or VF immunization.  To 
verify this, we examined the induction of cytolytic activity 
in  immune  splenocyte  cultures  obtained  from  BALB/c 
mice  primed  with  recombinant  vaccinia virus  expressing 
either RSV-F or RSV-G glycoprotein and restimulated in 
vitro with live RSV. 
As  reported previously  (13),  immune  splenocytes from 
BALB/c mice primed with VF exhibited cytolytic activity 
on histocompatible RSV-F-expressing targets when tested 
5  d  after in vitro  stimulation with  RSV-infected stimula- 
tors.  Immune  splenocyte cultures from VG-primed mice, 
on the other hand,  exhibited no  specific cytolytic activity 
on RSV-G-expressing target cells over a  range of effector 
to target ratios (Fig. 2 A). Target cells infected with a con- 
trol vaccinia virus  (VSCll)  or  uninfected  target  cells  (not 
shown)  were  not  lysed by either immune  cell population 
(Fig. 2 A). 
One  explanation for the lack of a memory CD8 +  CTL 
response to RSV-G  is that the  expression of G  glycopro- 
rein in vaccinia vires-infected cells inhibits vaccinia repli- 
423  Srikiatkhachorn and Braciale 90 
70 
60 
c~ 
•  ~  50 
: 
30 
20 
10 
0 
"Jr-  VG 
---4,-  VG22K 
2.5  5  10  20 
E:T ratio 
Figure 3.  Target  cells express- 
ing  G/22K  protein  are  recog- 
nized by 22K-specific CTL. Tar- 
get cells infected with indicated 
recombinant vaccinia virus were 
tested in a standard 5~Cr assay for 
recognition  by  22K-specific 
CTL generated from splenocytes 
of mice previously primed with 
V22K. Note that target cells in- 
fected with recombinant vaccinia 
virus expressing  the native RSV-G 
glycoprotein  were  not  recog- 
nized by 22K-specific CTL. 
Figure  4.  Splenocytes  from 
mice primed with VG22K, but 
not VG or VSC11 exhibit 22K- 
specific cytolytic activity. Sple- 
nocytes from mice primed with 
VSCll,  VG,  or  VG22K were 
stimulated in  vitro with  RSV- 
infected spleen cells. Cytolytic  ac- 
tivity against target cells infected 
with V22K (gray bar) or control 
vaccinia virus VSC11 (black bar) 
was analyzed in a standard SICr 
assay. 
cation  and  thereby  leads  to  inefficient  priming  of either 
RSV-G or vaccinia-specific memory CD8 + T  lymphocytes. 
To  address  this  possibility,  the  immune  splenocytes  from 
the  VG-  or VF-primed  mice  examined  above  (Fig.  2  A) 
were also restimulated in parallel with a control vaccinia vi- 
res  (VSCU) expressing no RSV gene products to assess the 
capacity of the two recombinant vaccinia viruses to prime 
for an  in  vitro  secondary vaccinia-specific  CTL  response. 
As  Fig.  2  B  shows,  the magnitude  of the vaccinia-specific 
CTL response in immune  splenocytes from VF- and VG- 
primed mice is  comparable.  This finding indicates  that the 
expression of RSV-G in vaccinia-infected antigen present- 
ing cells  did not affect the processing of vaccinia epitopes 
and  their  presentation  by  MHC  class  I  molecules  or  the 
priming  of vaccinia-specific  memory  CD8 +  T  lympho- 
cytes. 
CD8  +  Cytolytic  T  Lymphocyte  Recognition  of a  Chimeric 
RSV-G  Glycoprotein/22K Matrix Protein Product.  If the in- 
duction  of a  Th2-1ike  CD4 ÷  T  cell  response  and pulmo- 
nary  eosinophilia  after RSV  challenge  were  linked  to  the 
failure  of G  glycoprotein to prime a CD8 ÷  T  lymphocyte 
response,  then  immunization  of mice  with  an  altered  G 
protein  capable  of priming both  RSV-specific  CD4 +  and 
CD8 +  T  lymphocyte  responses  should  result  in  reduced 
lung eosinophilia after tkSV challenge. To examine this hy- 
pothesis,  we  constructed  a  mutant  G  gene  containing the 
amino acids residues 82 to 90 of the IkSV 22K matrix (M2) 
protein (see Materials and Methods,  Fig.  1).  The RSV ma- 
trix protein  has been shown to be an important target for 
MHC  class I-restricted CD8 + T  lymphocytes in both mice 
and humans (26, 27). In BALB/c mice, residues 82-90 have 
been  reported  to  be  a  dominant  matrix-specific  H-2  a- 
restricted CTL epitope (24, 28). 
When  expressed  in  a  recombinant  vaccinia  virus,  this 
mutant G/mattix chimeric protein  (VG22K) showed a sim- 
ilar pattern  of expression and glycosylation as wild-type G 
protein  (not shown).  When the  G/22K protein was tested 
for recognition by matrix-specific CTL generated by prim- 
ing of BALB/c mice with  recombinant vaccinia virus  ex- 
pressing RSV matrix  (M2  or 22K)  protein  (V22K)  and in 
vitro restimulation  with IkSV-infected splenocyte stimula- 
tors,  target cells infected with VG22K were recognized by 
22K-specific bulk spleen cells to the same extent as targets 
infected with V22K (Fig. 3).  This recognition is specific to 
the  22K  epitope  since  targets  infected with  VG were  not 
lysed  by  the  T  cells.  This  result  indicates  that  the  22K 
epitope, when expressed in the context of the RSV-G gly- 
coprotein,  was properly  processed  and presented  to  22K- 
specific cytolytic T  cells by target cells  in vitro. 
Pulmonary  Eosinophilia,  Cytokine Production and  Cytotoxic- 
ity in Mice Primed with the Chimeric G/22K Protein.  Since  the 
22K matrix epitope contained within the chimeric G/22K 
protein  could be processed in target cells  and presented to 
22K-specific  CTL,  it  was  of interest  to  determine  if the 
G/22K protein could prime for an in vitro secondary 22K- 
specific CTL response.  As Fig.  4  shows,  this  was the case. 
Immune  splenocytes  from  BALB/c  mice  primed  with 
VG22K mounted  a  vigorous in  vitro  secondary  CTL  re- 
sponse  detectable  at  day 5  after  the  in  vitro  restimulation 
with infectious RSV. Priming was specific for the 22K ma- 
trix  protein  since  target  cells  expressing  the  22K  matrix 
protein,  but not target cells infected with  control vaccinia 
virus (VSCll), were recognized by CTL. In contrast, sple- 
nocytes  from  mice  primed  in  parallel  with  vaccinia  virus 
expressing  wild-type  G  did  not  mount  a  detectable  CTL 
response on 22K expressing target cells  (Fig. 4). Also, sple- 
nocytes from mice primed with  the  control vaccinia virus 
(VSC11),  which  expresses  no RSV proteins,  also failed to 
mount  a  detectable  cytolytic response  on  22K-expressing 
target cells after in vitro stimulation  with RSV.  This latter 
finding suggests that the cytolytic activity on 22K-express- 
ing  targets  exhibited  by  G/22K  immune  splenocytes  was 
not due to a primary CTL response to the 22K matrix pro- 
tein induced in vitro by infectious RSV. 
If priming of an ILSV-specific CD8 + T  cell response ac- 
counts for the  difference in  the  pattern  of lung inflamma- 
tion between RSV-F and -G immune mice after intranasal 
RSV  challenge,  then  G/22K-immune  mice  should,  like 
F-immune  mice,  exhibit  minimal  eosinophil  accumulation 
after intranasal  RSV infection.  To examine  this  hypothesis, 
groups  of BALB/c  mice  were  primed  with  recombinant 
vaccinia virus expressing either RSV-F protein  (VF), wild- 
type  G  protein  (VG),  or  the  chimeric  G/22K  protein 
(VG22K),  and challenged 3  wk later with infectious RSV. 
BALB/c mice primed  with  the  VSCll  recombinant  vac- 
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cinia and challenged with RSV served as controls. 5 d later 
lungs of individual mice were harvested for histologic eval- 
uation of eosinophil accumulation or disrupted for isolation 
of infiltrating lung mononuclear cells. 
In agreement with earlier reports (12,  14),  priming with 
VG resulted in a marked perivascular eosinophil infiltration 
upon challenge with live RSV, as determined by quantita- 
tive morphometry (Fig.  5).  In contrast, pulmonary eosino- 
philia  among  VG22K-primed  mice  was  significantly  di- 
minished when  compared to  mice primed with VG,  and 
was comparable with mice primed with VF. Scattered foci 
of  eosinophil  infiltration  were  occasionally  observed  in 
some of the mice primed with VG22K, which probably re- 
flected variability in the response of individual mice to the 
22K epitope. 
We  previously  reported  that  antigen-dependent  cyto- 
kine production by mononuclear cells isolated at day 5 after 
intranasal  RSV  challenge  from  the  lungs  of RSV-F-  or 
RSV-G--primed mice directly correlates with  the  type  of 
pulmonary inflammatory response demonstrable histologi- 
cally in these primed animals at day 5 after RSV challenge 
(14).  Thus,  lung mononuclear cells  isolated from infected 
G-primed mice secreted high levels of IL-4 and particularly 
IL-5  commensurate  with  the  eosinophil  accumulation  in 
the lungs of these animals. A similar analysis was carried out 
on  lung  mononuclear  cells  from  RSV-challenged  mice 
primed with VF, VG, or VG22K. Fig. 6 showed the cyto- 
kine  production  by  mononuclear  cells  isolated  from  the 
lungs  of these  animals in response to RSV  stimulation in 
vitro.  As reported previously  (14),  cells  isolated from the 
VF-primed animals produced high levels of IL-2 and IFN-% 
Consistent with the histologic findings reported above (Fig. 
5),  cells isolated from mice primed with VG, on the other 
hand,  secreted high levels of IL-4 and IL-5. Low but de- 
tectable levels of IL-4 and IL-5 were found in the culture 
supernatants of lung cell cultures from VF-primed animals. 
Also consistent with the histologic finding, the levels of the 
Th2 type cytokines (IL-4 and IL-5) produced by infiltrat- 
ing lung mononuclear cells from mice primed with VG22K 
were  markedly  lower  than  the  levels  produced  by  cells 
from  mice  primed  with  recombinant  vaccinia  virus  ex- 
pressing the native RSV-G glycoprotein and were compa- 
rable to the levels detected in the VF-primed animals.  IFN-7 
production  by  lung  mononuclear  cells  were  comparable 
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Figure  6.  Cytokines produced by cells isolated from lungs of mice 
primed with recombinant vaccinia virus and challenged with RSV. Mice 
were primed with indicated recombinant vaccinia virus and challenged 
with live RSV intranasally 3 wk after priming. Mononuclear cells were 
isolated from lungs of these mice 5 d after challenge and stimulated with 
RSV. Supernatants were collected 48 h later and analyzed for cytokines 
by ELISA. 
among mice  primed with  G,  G22K,  or  F.  As  expected, 
cells isolated from the lungs of RSV-infected mice primed 
with the control recombinant vaccinla (VCSll)  produced 
low or nondetectable levels of all cytokines. 
Although immunization with the G/22K chimeric pro- 
tein did not evoke pulmonary eosinophilia after intranasal 
RSV challenge, the G/22K protein did appear to efficiently 
prime for a memory T  lymphocyte response. This was evi- 
dent both from the  extent  of lung inflammation in  these 
mice in response to RSV challenge (which was comparable 
to  that of wild-type  G- or F-primed mice)  and from the 
magnitude  of the  cytokine response of lung mononuclear 
cells  collected  after RSV  challenge  that  was  considerably 
higher than that of control nonimmune mice (Fig.  6). 
To further establish that the G/22K can efficiently prime 
an RSV-specific memory T  lymphocyte response, we ex- 
amined the cytokine response of immune splenocytes from 
VG- and VG22K-primed mice to in vitro stimulation with 
RSV.  As  Fig.  7  shows,  G-immune  and  G/22K-irnmune 
splenocytes produced comparable levels of IL-2 in response 
to RSV suggesting that the wild-type G  and the chimeric 
G/22K proteins induced a comparable expansion of IL-2- 
producing  memory T  lymphocytes.  It is  also  noteworthy 
that  neither  G/22K-  nor  G-immune  splenocyte  cultures 
produced detectable IL-4 or IL-5 after a single cycle of in 
vitro stimulation with RSV (data not shown). This result is 
consistent with our earlier findings that RSV-specific memory 
CD4 +  T  lymphocytes in  the  spleen,  unlike  the  polarized 
effector populations found in the lung after RSV infection, 
produce  predominantly  IL-2 and  IFN-7  after the  first in 
vitro stimulation with antigen (14). The high level oflFN-7 
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Figure 7.  VG22K  effectively  primes for RSV-specific memory T lym- 
phocyte response. Splenocytes  from mice previously  primed with VG or 
VG22K were stimulated in vitro with RSV-infected naive spleen cells. 
Supernatants were collected 48 h later and analyzed for IL-2, IL-4, IL-5, 
and IFN-% IL-4 and IL-5 were not detected in culture supernatants from 
either group of  animals (data not shown). 
produced by immune splenocytes from mice primed with 
VG22K most likely reflects  the  activation  of 22K-specific 
CD8 + T  cells in these bulk cultures. 
Priming with  V22K Results in Decreased Pulmonary Eosino- 
philia in Mice Sensitized to RSV-G Glycoprotein.  Our  results 
indicate  that  priming  for a  CD8 + T  cell  response  to  the 
22K epitope in the context of RSV-G glycoprotein reduced 
Th2  response  and  lung  eosinophilia  upon  challenge  with 
RSV.  However, insertion  of this epitope into the RSV-G 
glycoprotein could alter immune recognition of the RSV-G 
glycoprotein and result-in  the reduction of eosinophil in- 
filtration independent of the priming of CD8 + T  cell mem- 
ory response. To examine this issue, we immunized mice with 
a  combination of VG and V22K to simultaneously prime  a 
memory CD4 + T  lymphocyte response to G  glycoprotein 
and  a memory CD8 +  T  lymphocyte response  to the  22K 
matrix epitope without altering the RSV-G structure. 
Fig.  8  shows  the  result  of a  quantitative  morphometric 
analysis of lung eosinophil numbers after RSV challenge in 
mice primed with VG alone or with a mixture  of VG and 
V22K, or VG22K and V22K.  Priming with the combina- 
tion of V22K and VG resulted in a significant reduction in 
the number of eosinophils found around the blood vessels 
when  compared  to  the  mice  that  were  primed  with  VG 
alone.  An  even  greater  reduction  was  observed  in  the 
group of mice primed with the combination of V22K and 
VG22K. This result suggests that altered immune recogni- 
tion of G  in the chimeric G/22K protein does not account 
for  the  diminished  eosinophiha  evoked  by  this  protein. 
This finding also suggests a direct role of CD8 + T  cells in 
the regulation ofeosinophil recruitment into the lungs dur- 
ing RSV infection. The more effective suppression of tissue 
eosinophilia in mice co-primed with the V22K and VG22K 
is most likely due  to a more effective priming of a strong 
memory CD8 + T  cell response by this combination of vi- 
ruses. 
Pulmonary  Eosinophilia  in  CD8  +  T  Lymphocyte-deficient, 
~2m Knockout Mice.  The  findings  so  far  suggest  that  the 
induction  of a  memory CD8 +  T  lymphocyte response  to 
RSV suppresses lung eosinophilia and downregulates  IL-4 
and IL-5 production in RSV-G immune mice after intra- 
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Figure 8.  Priming  with V22K 
results in  decreased pulmonary 
eosinophilia in mice sensitized to 
RSV-G glycoprotein. Mice were 
primed with a single or a mix- 
ture of  two recombinant vaccinia 
viruses  as  indicated and  subse- 
quently  challenged with RSV 
intranasally. Mice were killed 5 d 
later,  and  lung  sections were 
stained for eosinophils. Eosino- 
phils  around  the  blood vessels 
were counted and the lengths of  the vessels were measured by micrometer. 
Each data point represents cell counts from individual animals. 
nasal RSV challenge. If this is the case, then priming to ei- 
ther  RSV-F  or  RSV-G  in  CD8 +  T  cell-deficient  mice 
should result in enhanced pulmonary eosinophilia with RSV 
challenge.  Figs.  9  and  10  show the  results  of this  analysis 
carried out in [32m-deficient ([32mKO) mice. 
As  observed  in  RSV-G-primed  conventional  mice, 
132mKO  mice  primed  with  VG  showed  extensive  lung 
eosinophil  accumulation  after  RSV  challenge  (Fig.  9  A). 
However, unlike RSV-F immune conventional mice, [32mKO 
mice primed  with VF show extensive  pulmonary eosino- 
philia  in  response  to  RSV  challenge  (Fig.  9  B).  Control 
132mKO mice primed with the control VSC11 vaccinia vi- 
rus  showed  no  eosinophil  accumulation  after  RSV  chal- 
lenge (Fig. 9  C). 
Fig.  10  shows  a  quantitative  morphometric  analysis  of 
lung  eosinophil  numbers  in  groups  of L32mKO  primed 
with VG, VF, or VSC11. This analysis reveals that the ex- 
tent of pulmonary eosinophilia in RSV-F- and -G-immune 
animals is comparable. It is also noteworthy that the magni- 
tude  of lung  eosinophil  accumulation  is  four-  to  fivefold 
higher on [32mKO mice than in conventional mice. Also, 
as  the  morphometric  data  on [32mKO  mice primed  with 
the control VSCll  virus suggests this enhanced eosinophil 
response in these  animals is dependent  upon earlier  expo- 
sure to RSV antigens and not due to an abnormal or exag- 
gerated response of [32mKO mice to exposure to infectious 
vaccinia virus during priming or to RSV virus during chal- 
lenge. 
Discussion 
In  the  studies  described  above,  we  have  demonstrated 
that priming for a  CD8 + T  cell response  resulted  in a re- 
duction  in  the  production  of IL-4  and  IL-5  in  BALB/c 
mice sensitized to RSV-G glycoprotein. This reduction in 
a Th2 type cytokine response correlated with the suppres- 
sion of eosinophil recruitment into the lungs of these mice. 
This effect was observed by priming either with a recombi- 
nant  vaccinia  virus  expressing  RSV-G  glycoprotein  in 
which a strong CD8 + T  cell epitope from RSV-M2 pro- 
tein has been inserted  (VG22K)  or with a combination of 
vaccinia  virus  expressing  the  22K  (M2)  protein  and  the 
RSV-G glycoprotein, respectively. The importance of CD8 + 
426  Downregulation of Th2 Response by Virus-specific CD8 + T Cells Figure  9.  Lung  histopathology of 132mKO 
mice  sensitized to  RSV  glycoproteins. Mice 
were primed with VG (A), VF (B), or VSC11 
(C) and challenged  with live RSV intranasally  3 
wk after priming. Mice were killed 5  d  after 
challenge, and lung  sections were  stained for 
eosinophils with Leinert-Giemsa stain. Original 
magnification:  200. 
T  cells in this process was further supported by the results 
in  CD8 +  T  cell-deficient,  [32mKO  mice.  In  these  mice, 
priming  to  RSV-F  glycoprotein,  which  in  normal  mice 
primes for a strong cytolytic response and a pulmonary in- 
filtrate consisting primarily of mononuclear  cells on  RSV 
challenge, resulted in the development of marked pulmo- 
nary eosinophilia that was not seen in mice with an intact 
CD8 + T  cell compartment. 
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CD8 +  T  cells can potentially regulate the differentiation 
and activation ofCD4 + T  cells at various stages of differen- 
tiation  (29,  30).  Most  studies  on  the  factors  that  regulate 
the  differentiation of CD4 ÷  T  cells have  focused  on  the 
differentiation of naive CD4 ÷ T  cells to Thl  or Th2 effec- 
tor T  cells (16,  18,  31,  32).  Recent studies have indicated 
that  the  differentiation  of memory  CD4 +  T  cells  is  also 
regulated by the same mechanisms that regulate the differ- 900- 
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Figure 10.  Perivascular  eosin- 
ophils in  the lungs of ~2mKO 
mice sensitized to  KSV glyco- 
proteins. Mice were primed with 
the  indicated recombinant vac- 
cinia virus 3 wk before intranasal 
challenge with RSV. Mice were 
killed 5 d later and lung sections 
were  stained  for  eosinophils. 
Eosinophils  around  the  blood 
vessels were  counted  and  the 
lengths of the vessels were mea- 
sured by micrometer. Note that 
the magnitude of  lung eosinophiha is four to five times higher in 132mKO 
mice than BALB/c mice. 
entiation of naive CD4 + T  cells toward a Thl  or Th2 ef- 
fector phenotype  (33,  34).  In this  connection,  it  is  note- 
worthy that  immunization with RSV-G in the  form of a 
recombinant  vaccinia  virus  primes  for  a  vaccinia-specific 
memory  CD8 +  CTL  response.  Yet  G-specific  memory 
CD4 + T  lymphocytes primed by this mechanism still  give 
rise to effector cells producing high levels of IL-4 and IL-5 
upon challenge with RSV. This result suggests that the en- 
vironment in which the naive G  specific CD4 ÷ T  cells dif- 
ferentiated,  i.e.,  in the presence  of activated vaccinia-spe- 
cific CD8 + T  cells  did not dictate the eventual phenotype 
of the effector CD4 + T  cells  generated from the G-specific 
memory  CD4 +  T  cells  in  response  to  RSV  challenge. 
Rather,  in this model at least,  CD4 + T  cell differentiation 
into activated effectors can be regulated by antigen-specific 
CD8 +  T  lymphocytes at  the  level  of the  antigen-specific 
memory CD4 + T  cells. 
It is not clear if CD8 + T  cells regulate the cytokine re- 
sponse of CD4 + T  cells by acting at the level of memory 
CD4 +  T  cells  or differentiated  effector CD4 +  T  cells  de- 
rived from activated memory CD4 + T  cells.  In one report, 
adoptive transfer of activated RSV-22K-specific CD8 ÷ CTL 
along with activated RSV-G-specific (IL-4- and IL-5-pro- 
ducing)  CD4 + T  cells markedly diminished  the  degree of 
pulmonary  eosinophilia  normally seen  when  only G-spe- 
cific CD4 + T  cells were transferred before RSV challenge 
(8).  Since long-term lines of activated CD4 + and CD8 + T 
cells were used in this study, the downregulation of eosino- 
philia was due to an effect of activated 22K-specific CD8 + 
T  cells on the function of an activated population of G-spe- 
cific  CD4 +  T  cells  with  a  Th2-1ike  effector  phenotype. 
The  findings  reported  here  are  in  agreement  with  the 
above results  and suggest that  CD8 +  T  cells  may regulate 
the cytokine response of CD4 + T  cells  at various stages of 
CD4 + T  cell activation and differentiation.  Further analysis 
will be required to define the stages ofCD4 + T  cell activa- 
tion/differentiation  that  are  susceptible  to  CD8 +  T  cell 
regulation. 
The mechanisms that regulate the differentiation of CD4 + 
T  cells toward the Thl or Th2 effector pathways have been 
recently reviewed  (16,  35).  Perhaps  the  best  documented 
mechanism is the polarizing effect of certain cytokines on 
the differentiation of CD4 ÷ T  cells (36). In particular,  IL-4 
and IL-12 have been shown to skew the differentiation  of 
CD4 +  T  cells  toward  a  Th2  or Thl  phenotype,  respec- 
tively (17,  19, 32). Upon activation, CD8 + T  cells secrete a 
number of soluble mediators that can potentially affect the 
differentiation  of CD4 +  T  cells.  In  the  RSV  model  de- 
scribed  here,  IFN-'v would  appear  to be  the  most likely 
candidate cytokine. It has been well documented that IFN-~ 
can suppress the proliferation ofTh2 CD4 ÷ T  cells and that 
the presence of IFN-'v during CD4 + T  cell activation/dif- 
ferentiation  favors  the  development  of Thl  type  effector 
cells  (37).  However,  several  observations  argue  against 
IFN-~/  as  the  CD8 ÷  T  cell  effector  molecule  regulating 
CD4 ÷  T  cell  differentiation  in  the  R.SV  model.  First,  as 
noted above, the priming ofRSV-G--specific CD4 + T  cells 
using a  recombinant vaccinia virus would be  expected  to 
result in a high level of IFN-~/production by activated vac- 
cinia-specific  CD8 +  (and  CD4 ÷)  T  lymphocytes  during 
priming with the recombinant vaccinia virus. Nonetheless, 
G-specific memory CD4 + T  cells were not skewed toward 
a  Thl  effector  pathway.  More  importantly,  as  reported 
here and elsewhere,  G-specific CD4 ÷ T  cell effectors pro- 
duce high levels of IFN-'v at the site of RSV challenge in 
the lung, but still  secrete high levels oflL-4 and IL-5 (14). 
Finally, we previously reported that mice rendered geneti- 
cally deficient in  IFN-',/ production by targeted  gene dis- 
ruption had the same pattern of pulmonary inflammation as 
conventional mice  after priming with  RSV-F  or RSV-G 
and challenge with RSV (14).  Taken together,  these find- 
ings suggest that products of activated CD8 + T  cells other 
than IFN-~/may play a dominant role in regulating CD4 + 
T  cell  differentiation.  Additional  studies  will be  necessary 
to examine this possibility. 
Both  antigen  dose  and  antigen  form have  been  impli- 
cated as important regulators  of effector CD4 + T  cell dif- 
ferentiation along a Thl-like or Th2-1ike pathway (11, 38, 
39, 40). In particular,  the role of antigen dose in regulating 
Th2  differentiation  of CD4 +  T  cells  is  controversial  (39, 
40). For example,  sensitization to aeroallergens and allergic 
responses  occur at  extremely  low  antigen  doses  sustained 
over a prolonged period,  whereas  in many models of mi- 
crobial infection, Th2-1ike responses are frequently associ- 
ated with  chronicity and a high microbial antigen burden 
(41, 42). Since RSV-specific CD8 + CTL have been shown 
to promote virus clearance from the lungs in experimental 
RSV infection (8),  the regulatory effect ofCD8 + T  cells on 
memory CD4 +  T  cell differentiation  into  Th2-hke  effec- 
tors could reflect an effect of CD8 + CTL effectors on R.SV 
antigen load. Thus, mice primed with the RSV-F, 22K, or 
the  G/22K  chimeric protein  would produce  CD8 +  CTL 
in response to RSV challenge. This would, in turn, lead to 
more accelerated virus clearance from lungs than occurs in 
RSV-G-primed mice that lack memory CD8 + T  cells.  Ac- 
cording to this view, a higher virus load and prolonged an- 
tigen availability  would favor the differentiation of G-specific 
memory CD4 +  T  cells  into  effector cells with a Th2-1ike 
phenotype.  Our observation that  G-specific memory CD4 + 
T  cells require multiple rounds of in vitro stimulation with 
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is consistent with this interpretation. 
Although the concept of viral load as a primary regulator 
of RSV-specific CD4 + T  cell differentiation in the lung is 
attractive, there is little  direct experimental support for it. 
In particular, a number of reports using either RSV virion 
subunits, inactivated vaccines, or vaccinia recombinants (in- 
cluding VF and VG) to prime mice have demonstrated that 
with any of these priming schemes, infectious virus can not 
be detected in the lungs of mice by 4-5 d after RSV chal- 
lenge (22,  43-46). Therefore, ifRSV antigen persistence in 
the lung is influencing T  lymphocyte activation/differenti- 
ation, persistent antigen may not be reflected in the infec- 
tious virion content of the lungs. Also, we cannot exclude 
the possibility that there is a subtle difference in the kinetics 
of virus clearance or the magnitude of virus replication in 
the lungs of VG- and VF-primed mice that might account 
for the  dramatic differences in  T  cell effector phenotypes 
after RSV  infection.  Studies  to  examine  these  issues  are 
currently i n progress. 
Our findings in the  [32mKO mice provide further sup- 
port for a role of CD8 + T  cells in the control of CD4 + T 
cell  differentiation. 132mKO mice lack mature CD8 + T  cells 
and,  when  primed  with  either  VF  or  VG,  develop  a 
marked eosinophilia upon  challenge with live RSV.  Sev- 
eral aspects of this result are noteworthy. First,  the magni- 
tude of eosinophilia in these animals are four to five times 
higher than conventional BALB/c mice. This may be due 
to more extensive replication of recombinant vaccinia virus 
in these mice because they lack a vaccinia-specific CD8 + 
CTL response. This, in turn, could result in a higher dose of 
RSV-F and RSV-G and more effective priming of RSV- 
specific CD4 + T  memory cells. Second, the absence of [32m 
in these animals may result in a deficiency of MHC  class 
I-dependent,  CD8 +, ~//8 TCR-expressing T  cells.  ~//8 T 
cells  have been  reported  to  suppress  allergic  responses  in 
the lung (47, 48). The absence of this regulatory T  cell sub- 
set could lead to the exaggerated Th2 response and tissue 
eosinophilia  observed by us  in  these  animals.  Third,  the 
ability of these  animals to  develop a  strong Th2  type re- 
sponse  argues  against  a  requirement  for  CDl-restricted 
NKI.1 +, CD4 + T  cells  (49) in the differentiation of CD4 + 
T  cells toward a Th2 phenotype in this model. Our results 
are in agreement with recent reports which also showed the 
induction of Th2 responses  to unrelated antigens in [32mKO 
mice (50,  51). 
A  number of factors appear to  determine whether epi- 
topes present in a foreign protein are processed, presented, 
and recognized by CD8 + CTL (52).  In the case of RSV-G, 
the  reason  for  the  inability  of this  viral  glycoprotein  to 
stimulate CD8 + CTL is not clear. Inspection of the amino 
acid sequence  of G  indicates that it has multiple potential 
peptide fragments with the appropriate MHC-binding mo- 
tif for interaction with H-2  a haplotype MHC class I mole- 
cules  (53,  54).  Based on our analysis  of the recognition of 
the G/22K chimeric protein by CTL, the expression of the 
RSV-G protein in infected cells does not interfere with an- 
tigen-processing and -presentation events along the MHC 
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class  I-presentation  pathway,  nor  does  its  structure  pre- 
clude efficient processing and presentation of epitopes con- 
tained within the protein. 
A  relationship  between  viral respiratory tract  infection 
and  the  exacerbation  of allergic  airway  diseases  has  long 
been appreciated. Emerging experimental evidence has be- 
gun to reveal the mechanisms by which respiratory viruses 
potentiate the release of proinflammatory mediators by in- 
fected airway epithelial cells  and sensitized mast cells from 
allergic individuals (55,  56). The mechanisms by which vi- 
ral respiratory tract infections influence the development of 
allergic  airway diseases,  however,  remain unclear.  Several 
studies  have  shown  that  lower  respiratory  tract  infection 
with RSV is an important risk factor for the  subsequent 
development of asthma (57,  58). It is therefore tempting to 
speculate that in individuals with a genetic predisposition to 
atopic responses,  immune responses  to respiratory viruses such 
as RSV may alter the immune response and, in particular, 
the pathway of CD4 + T  cell differentiation in response to 
aeroallergens present concomitantly or subsequently in the 
airways.  Therefore, in some individuals,  the  development 
of a  CD4 + T  cell response to  a virus in the absence of a 
CD8 + T  cell response may not only lead to a strong Th2 
type response to viral antigens, but also provide a cytokine 
milieu  conducive to  CD4 + Th2 responses to  "bystander" 
aeroantigens. This could in turn lead to the subsequent de- 
velopment of an allergic airway disease. 
At present there is no  effective vaccine against primary 
RSV infection in infants and children.  In an early clinical 
vaccine  trial  using  a  formalin-inactivated  whole  virion 
RSV preparation to vaccinate seronegative infants and chil- 
dren, administration of this inactivated vaccine resulted in a 
paradoxical response in vaccine recipients upon subsequent 
natural  RSV infection  (59,  60).  Vaccine recipients exhib- 
ited an exaggerated pulmonary inflammatory response after 
natural infection, which resulted in enhanced morbidity and 
mortality compared to unvaccinated controls and a promi- 
nent eosinophil response in peripheral blood and lung tis- 
sue indicative of a Th2  type response  (59).  Immunization 
of mice with formalin-inactivated RSV also induces a Th2 
pattern of lung inflammation and cytokine production after 
challenge with RSV (11).  The findings reported here pro- 
vide an explanation for the effect of  formalin-inactivated RSV 
in  children  and experimental animals. Efficient processing 
and presentation of viral proteins to CD8 + T  lymphocytes 
requires  access to  the  MHC  class I presentation pathway, 
usually by de novo expression of viral gene products in the 
infected cell (61). Viral proteins in formalin-inactivated RSV 
virion preparations are unlikely to be efficiently processed 
and presented to CD8 + T  cells, but should efficiently enter 
the  MHC  class  II processing pathway for presentation  to 
CD4 +  T  cells.  Therefore,  in  the  aforementioned  clinical 
trial,  formalin-inactivated RSV may have primed a mem- 
ory RSV-specific CD4 + T  cell response in vaccine recipi- 
ents  without  effective CD8 +  T  cell priming in  a  fashion 
analogous to the VG priming reported here. The activation 
of memory CD4 +  T  cells  after natural  RSV infection  of 
children  or  experimental  animals  without  a  concomitant response of RSV-specific memory CD8 + T  cells would then 
result  in  the  exaggerated  Th2-llke  inflammatory  pattern 
observed in lungs of the inactivated vaccine recipients. The 
pronounced Th2-1ike response to inactivated RSV vaccine 
seen in both human subjects and experimental animals fur- 
ther underscores the potential importance of CD8 + T  cells 
in  downregulating  CD4 +  Th2-1ike  effector  T  cell  re- 
sponses (62). 
Since CD8 +  T  cells  have also been implicated  as  effec- 
tors in immune-mediated injury during experimental RSV 
infection  (8,  63),  an  effective vaccine  strategy against  this 
virus will require  the priming of a protective MHC  class 
I-restricted cytolytic CD8 + T  cell response. Enhancement 
of a protective cytolic T  cell response might be achieved by 
manipulating  the  cytokine  environment  during  the  initial 
priming,  as  has  been  observed  in  studies  of the  effect  of 
anti-IL-4 antibody on the response of mice to 1KSV infec- 
tion after vaccination with inactivated RSV (64).  A  better 
understanding of the complex interplay between 1KSV and 
the immune  effectors that  respond  to it will be  crucial to 
the development of an effective immunoprophylactic agent 
against this virus. 
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